Close Menu
    Trending
    • Aayush Wellness’s FY25 Revenue Rockets 8,645%, Net Profit Soars 489%
    • Aristo Bio-Tech FY25 PAT Rises to Rs 4.06 Cr, Revenue Jumps 30 Percent to Rs 318.09 Cr
    • IFL Enterprises Ltd reports stellar turnaround in FY25; PAT up 348 Percent Y-o-Y to Rs. 3.04 crore in Q4FY25
    • How Tina Walia carves a Blueprint for a Powerful Presence
    • Deliure Unveils Exclusive Tres Leches Cakes for Mumbai’s Dessert Lovers
    • WARF Invites Colleges to Join India’s Top 2025 Ranking Survey for Engineering, Medical, MBA and Law
    • Maximus International’s Momentum Continues: Strategic Investments Fuel 26 Percent EBITDA Growth
    • Profin Range of Aluminium Profiles by Hafele
    Republic News TodayRepublic News Today
    • Business
    • Entertainment
    • Education
    • Health
    • Lifestyle
    • National
    • World
    • Press Release
    Republic News TodayRepublic News Today
    Home»Business»Vaishali Pharma received orders worth USD 73.85 million (Approx Rs. 600 crore) from overseas buyers
    Business

    Vaishali Pharma received orders worth USD 73.85 million (Approx Rs. 600 crore) from overseas buyers

    By March 1, 2023No Comments4 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Mr. Atul Vasani, Managing Director, Vaishali Pharma

    Mumbai (Maharashtra) [India], March 1: Mumbai based Vaishali Pharma Ltd has received orders worth USD 73.85 million (Approx. Rs. 600 crore) from overseas buyer for purchase of Antibiotics Pharmaceutical products. Company has completed the due diligence with the overseas partners and have discussed various prospects for the long-term relations and look forward to achieve more orders from them. This order will be executed within 6 to 8 months and subject to initial advance payment as per the agreed terms of the contract.

    Vaishali Pharma Limited is one of the fastest-growing and versatile companies in the pharmaceutical industry. It has a strong presence in both the domestic and export markets and is currently a supplier to all leading Indian and multinational pharmaceutical companies. The company has been catering to semi-regulated and nonregulated markets across the globe. Company holds altogether 250+ Brands in Finished Formulations, Registered in International Market.

    Commenting on the development, Mr. Atul Vasani, Managing Director, Vaishali Pharma Ltd said, “We are happy to share the news that, we have received the order worth 73.85 Million USD with an overseas buyer for purchase of Antibiotics Pharmaceutical products. This is the result of correspondence with them since last 6 months. This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months. As per our Company’s policy we have done the Due diligence and respective contracts with the overseas Company. We have discussed various prospects with the company for the long term relations and also we look forward to achieve more orders from them.”

    Established in 1989, Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products – Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary supplements, Herbal & Nutraceutical products, with a well-established brand known for its high-quality products & services amongst various clients globally. The company has over 250 + formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The company has built a robust pipeline of around 250 Dossiers. The Company’s synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

    Company is engaged in supply of pharmaceutical products to corporates, hospitals and retails stores in all SKUs required. Company’s products have made its grasp on the overseas market and getting excellent feedback worldwide. The Company is showing consistent agility and innovation by meeting the needs of its customers in both Domestic and International markets.

    Vaishali Pharma Limited, continue to remain steadfast in our transformation journey, building additional pathways of growth and simultaneously focusing on making the organisation more efficient, and believe that the “Quality is an ongoing process of building and sustaining relationship.” Our strong commitment of providing quality products is boosted by in-depth industry knowledge, well-qualified team of professionals, as well as hi-tech and advanced infrastructure, resultantly, creating mutually beneficial associations for all parties involved.

    “Quality being the primary goal of our association, is the Strength of our Partnership. We have strong foothold in sourcing various products in India. Wherein Vaishali Pharma, is a 30 years old pharmaceutical organization, entirely involved in International Business Marketing of Pharmaceutical Products; along with Nutraceutical Products for Domestic and International Market. Our International associations are entirely backed by the Quality Norms we adhere for All Our Products. This will help Company to achieve milestone and reach to new heights,” said Mr. Vasani.

    If you have any objection to this press release content, kindly contact [email protected] to notify us. We will respond and rectify the situation in the next 24 hours.

    Business
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleDissemination of Key messages of Achhi Aadat Campaign through Public Transport (Autorickshaws) in New Delhi
    Next Article Industry gearing up for Asia’s largest show on woodworking, furniture manufacturing & mattress manufacturing – DELHIWOOD 2023

    Related Posts

    How Tina Walia carves a Blueprint for a Powerful Presence

    May 31, 2025

    Top 7 Reasons Gamers Should Consider the TCL Q6C Series

    May 30, 2025

    ILIOS 72 Raises INR 1 Cr Seed Funding to Expand Access to Alternative Investments

    May 30, 2025
    Recent Posts
    • Aayush Wellness’s FY25 Revenue Rockets 8,645%, Net Profit Soars 489%
    • Aristo Bio-Tech FY25 PAT Rises to Rs 4.06 Cr, Revenue Jumps 30 Percent to Rs 318.09 Cr
    • IFL Enterprises Ltd reports stellar turnaround in FY25; PAT up 348 Percent Y-o-Y to Rs. 3.04 crore in Q4FY25
    • How Tina Walia carves a Blueprint for a Powerful Presence
    • Deliure Unveils Exclusive Tres Leches Cakes for Mumbai’s Dessert Lovers
    • WARF Invites Colleges to Join India’s Top 2025 Ranking Survey for Engineering, Medical, MBA and Law
    • Maximus International’s Momentum Continues: Strategic Investments Fuel 26 Percent EBITDA Growth
    • Profin Range of Aluminium Profiles by Hafele
    • Business Outline Announces the Business Elite Award | Recognising Exceptional Business Leaders and Companies
    • Greenman Viral Desai to Launch 7-Day Tree Plantation Drive on World Environment Day

    Type above and press Enter to search. Press Esc to cancel.